Sign In
Buy VERX
$12.91
+0.310 (+2.46%)
At Close: Jul 31, 2026
Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3
04:00pm, Wednesday, 19'th Nov 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Fi
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November
07:15am, Monday, 17'th Nov 2025
Vertex's core business continues to drive strong financial results. The biotech has an exciting late-stage pipeline that could make significant progress in the next few years.
Alger SICAV - Alger Small Cap Focus Fund Q3 2025 Portfolio Update
08:07am, Sunday, 16'th Nov 2025
Nebius Group N.V. (NBIS), Talen Energy Corp (TLN), and Tutor Perini Corporation (TPC) were among the top contributors to performance. Wingstop, Inc. (WING), Portillo's, Inc. (PTLO), and Vertex, Inc. (
ABN Amro Investment Solutions Invests $3.22 Million in Vertex, Inc. $VERX
03:11am, Friday, 14'th Nov 2025
ABN Amro Investment Solutions bought a new stake in shares of Vertex, Inc. (NASDAQ: VERX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The in
5 Tech And Consumer Stocks At Risk Of Steep Declines
02:53pm, Wednesday, 12'th Nov 2025
As the market grows increasingly top-heavy, the risks for fundamentally weaker and average-strength companies are increasing. The number of stocks losing momentum over the past year has mounted as meg
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from
6 Impressive Stocks That Powered AI, Partnerships, And Performance Gains
01:40am, Friday, 07'th Nov 2025
Nebius will supply dedicated GPU infrastructure to power Microsoft's AI services, marking Nebius's first long-term contract with a major cloud service provider. Astera Labs shares contributed positive
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"
05:23pm, Tuesday, 04'th Nov 2025
Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. JOURNAVX drives revenue with strong acute pain demand an
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
11:46am, Tuesday, 04'th Nov 2025
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
After Plunging 17.7% in 4 Weeks, Here's Why the Trend Might Reverse for Vertex (VERX)
10:36am, Tuesday, 04'th Nov 2025
Vertex (VERX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Vertex Falls 10% After Reporting Mixed Q3 Results
06:52pm, Monday, 03'rd Nov 2025
Vertex (NASDAQ: VERX) delivered a split result this morning that left investors parsing mixed signals.
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs
04:20pm, Monday, 03'rd Nov 2025
Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer me
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book
04:12pm, Monday, 03'rd Nov 2025
Vertex stock dipped late Monday despite better-than-expected third-quarter metrics and a slight sales guidance boost.
Vertex Reports Third Quarter 2025 Financial Results
04:02pm, Monday, 03'rd Nov 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 fin
Vertex, Inc. (VERX) Q3 2025 Earnings Call Transcript
02:46pm, Monday, 03'rd Nov 2025
Vertex, Inc. ( VERX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Joseph Crivelli - Vice President of Investor Relations David DeStefano - CEO, President & Chairman of the
